Fikri Selçuk Şimşek

Fikri Selçuk Şimşek

Auto-generated profile, based on publicly available information

Fikri Selçuk Şimşek

Department of Nuclear Medicine, Pamukkale University Faculty of Medicine, Denizli, Türkiye

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
FDFadime Demir
Fadime Demir
FŞFikri Selçuk Şimşek
Fikri Selçuk Şimşek
TBTansel Ansal Balcı
Tansel Ansal Balcı
In this study, we aimed to investigate the predictive value of pre-ablative stimulated thyroglobulin (Tg) and Tg/thyroid-stimulating hormone (TSH) to identify lymph node metastasis (LNM) or distant metastases (DM) prior to radioactive iodine (RAI) treatment. Patients without metastasis were included in group 1 (n=100), those with LNM were included in group 2 (n=83), and those with DM constituted group 3 (n=23). Tg and TSH values were measured approximately 4 hours prior to RAI ablation therapy. There was a significant difference between group 3 and other groups (group 1 and group 2) in terms of Tg (p<0.001) and Tg/ TSH (p<0.001). For Tg level and Tg/TSH ratio, the areas under ROC were 0.990 [95% confidence interval (CI): 0.979-1] and 0.991 (95% CI: 0.981-1), respectively. The cut-off points for Tg and Tg/TSH were 102 ng/mL and 1.06, respectively. Our results suggest that Tg and Tg/TSH values can be used to predict DM. On the other hand, our study indicates that patients should be carefully evaluated for LNM even when Tg levels are l ow.

6 February 2026 in Head & Neck
Verified
Journal Article
Closed access
AGAziz Gültekin
Aziz Gültekin
MKMerve Yücel Kahraman
Merve Yücel Kahraman
TSTarik Sengoz
Tarik Sengoz
FŞFikri Selçuk Şimşek
Fikri Selçuk Şimşek

31 December 2020 in Tuberk Toraks
Verified
Journal Article
Closed access
EUErhan Uğurlu
Erhan Uğurlu
NÇNazlı Çetin
Nazlı Çetin
NYNilüfer Yiğit
Nilüfer Yiğit
ÜAÜmit Aydoğmuş
Ümit Aydoğmuş
IAIlknur Hatice Akbudak
Ilknur Hatice Akbudak
GAGoksel Altinisik
Goksel Altinisik
Bronchoscopic volume reduction treatments are among the important alternatives for selected emphysema patients with a dyspneic course despite optimal medical treatment. Our aim was to carry out a retrospective scan of the data for COPD patients subject to coil treatment at our center for assessing whether coil procedure has an impact on the respiratory symptom and pulmonary function tests in COPD patients. The data of 41 patients with severe emphysema and treated with coils between 2017-2020 were evaluated retrospectively. Cardiopulmonary rehabilitation programs were completed for all patients prior to the procedure and they were assessed with pulmonary function test (PFT), diffusing capacity for carbonmonoxide test (DLCO), body plethysmography, 6-minute walk test, ventilation/perfusion scintigraphy, St. George's Respiratory Questionnaire (SGRQ). Data acquired prior to the procedure and 3rd month control data after the procedure were recorded and SGRQ was applied via face-to-face interviews during the controls by doctors working on Pulmonary Diseases as was the case before the procedure. SGRQ questionnaires of 32 patients were evaluated. Statistically significant changes were observed after the procedure in symptom, activity, impact score and total score which were calculated prior to the procedure. Pre and post procedure FEV1, FVC, FEV1/FVC, PEF, FEF25/75 parameters were used for the comparison made via SFT. Statistically significant changes were observed in FEV1, FVC, FEF25/75 when the pre and post-procedure SFT parameters of the 32 patients included in the study were compared. A statistically significant improvement was observed in the PFT parameters and quality of life questionnaires following the coil procedure which is a bronchoscopic volume reduction procedure.

1 April 2015 in European Urology Supplements
Verified
Journal Article
Closed access
YTY. Tanidir
Y. Tanidir
AGA. Garayev
A. Garayev
ASA. Sahan
A. Sahan
TST.E. Sener
T.E. Sener
ITI. Tinay
I. Tinay
FSF. Simsek
F. Simsek

22 May 2026 in Anatolian Current Medical Journal
Verified
Journal Article
Closed access
TSTarik Sengoz
Tarik Sengoz
OÇOnur Cumhur Çimen
Onur Cumhur Çimen
AÇAli Çelik
Ali Çelik
AGAziz Gültekin
Aziz Gültekin
FŞFikri Selçuk Şimşek
Fikri Selçuk Şimşek
Aims: Lutetium-177 (Lu-177) PSMA radioligand therapy (PRLT) is an effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Treatment-related nephrotoxicity and hematotoxicity can occur. In our study, we investigated the development of nephrotoxicity and hematotoxicity after Lu-177 PRLT applied to mCRPC patients in our department.Methods: All patients diagnosed with mCRPC who applied to our department between March 2018 and May 2025 and received at least 3 courses of Lu-177 PRLT were included in the study. The study was designed retrospectively. Patient information was obtained from patient treatment files and the hospital system. Patients were divided into two groups: those who received 3 courses of Lu-177 PRLT (group 1) and those who received ≥4 courses of Lu-177 PRLT (group 2). For the evaluation of hematotoxicity and nephrotoxicity, blood values were used in group 1 patients before treatment (on the day of the first cycle) and at the end of treatment (1 month after the third and final cycle); and in group 2 patients before treatment (on the day of the first cycle), interim (1 month after the third cycle), and at the end of treatment (1 month after the final cycle). Hematological and renal toxicity were determined according to the “Common Terminology Criteria for Adverse Events (CTCAE v5.0)”. Results: The study included 43 male patients (16 (37.3%) in group 1, 27 (62.7%) in group 2). The mean age was 69.74±7.86 years. In group 1 patients, post-treatment glomerular filtration rate (eGFR), red blood cells (RBC), hemoglobin (Hb), hematocrit (Htc), platelets (PLT), white blood cell count (WBC), and lymphocyte values were statistically significantly lower than pre treatment values, while creatinine values were higher. In Group 2 patients, post-treatment and interim eGFR, RBC, Hb, Htc, mean corpuscular hemoglobin volume (MCV), mean corpuscular hemoglobin (MCH), PLT, WBC, and lymphocyte values were statistically significantly lower than pre-treatment values, while creatinine levels were higher. When toxicity was assessed according to CTCAE v5.0, nephrotoxicity was detected in 2 patients (grade 2 and 3) (4.7%) and hematotoxicity in 3 patients (grade 2, 3 and 4) (7%) after treatment. No significant differences were found between the groups that received/did not receive chemotherapy before Lu-177 PRLT, and between pre- and post-treatment blood parameters.Conclusion: Although post-treatment deterioration in blood parameters indicating hematological and nephrological side effects was observed in patients diagnosed with mCRPC following Lu-177 PRLT, toxicity assessment according to CTCAE v5.0 revealed low levels of hematotoxicity and nephrotoxicity. Lu-177 PRLT is a safe treatment that can be applied with appropriate patient selection and monitoring.

15 July 2026 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
MKMerve Yücel Kahraman
Merve Yücel Kahraman
FŞFikri Selçuk Şimşek
Fikri Selçuk Şimşek
TSTarik Sengoz
Tarik Sengoz
AGAziz Gültekin
Aziz Gültekin
IGILKNUR GIRISGEN
ILKNUR GIRISGEN
TBTülay Becerir
Tülay Becerir
Graft intolerance syndrome (GIS) is a relatively common but often overlooked clinical condition that may develop following renal graft failure. It usually occurs within the first year after resumption of dialysis. It is characterized by persistent inflammatory findings in the absence of infection and may adversely affect patient prognosis if not recognized in a timely manner. In this study, 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings of two renal transplant recipients with clinical suspicion of GIS are presented. In both cases, diffuse increased FDG uptake was observed in the graft parenchyma on PET/CT imaging. In one case, hypermetabolic lymph nodes observed in the para-aortic region were additionally evaluated as reactive. The diagnosis of GIS was established based on imaging findings together with clinical and laboratory data. FDG PET/CT can demonstrate characteristic inflammatory uptake patterns. It may also help exclude alternative etiologies such as infection or malignancy in the evaluation of GIS.